Skip to main content
Search all BMC articles
Experimental Hematology & Oncology
Table 1 MCL treatment algorithm
Mantle cell lymphoma and its management: where are we now?
R-HyperCVAD (Rituximab-Hyperfractionated cyclophosphamide, vincristine, Adriamycin and dexamethasone); Mod: modified; VcR-CVAD (bortezomib with modified R-HyperCVAD); CHOP (Cyclophosphamide, vincristine, doxorubicin and prednisone); RDHAP (Rituximab, dexamethasone, cytarabine and platinum); V (Bortezomib); VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin and prednisone); BTK: Bruton tyrosine kinase; mTOR: mechanistic target of rapamycin inhibitors; BiTE (Bi-specific T-cells Engager); CAR-T: chimeric antigen receptor-engineered T-cells
* Some trials did not include consolidation with ASCT
Back to article page